<div id="readability-page-1"><p>HighVista Strategies LLC increased its stake in shares of  Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 71.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 67,288 shares of the company's stock after purchasing an additional 28,002 shares during the quarter. Praxis Precision Medicines accounts for  1.0% of HighVista Strategies LLC's holdings, making the stock its 22nd biggest holding. HighVista Strategies LLC owned approximately 0.32% of Praxis Precision Medicines worth $2,829,000 as of its most recent filing with the SEC.</p><p>A number of other institutional investors also recently bought and sold shares of PRAX. Adage Capital Partners GP L.L.C. increased its position in  Praxis Precision Medicines by 188.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company's stock valued at $65,998,000 after acquiring an additional 1,137,748 shares during the last quarter.  Driehaus Capital Management LLC lifted its holdings in shares of  Praxis Precision Medicines by 192.0% in the 1st quarter. Driehaus Capital Management LLC now owns 481,598 shares of the company's stock worth $18,238,000 after acquiring an additional 316,686 shares during the last quarter.  Vivo Capital LLC purchased a new position in shares of  Praxis Precision Medicines during the 2nd quarter worth about $7,048,000.  Woodline Partners LP grew its holdings in  Praxis Precision Medicines by 1,666.5% during the 1st quarter. Woodline Partners LP now owns 175,727 shares of the company's stock valued at $6,655,000 after purchasing an additional 165,779 shares during the last quarter.  Finally, Aberdeen Group plc raised its position in  Praxis Precision Medicines by 143.5% in the 2nd quarter. Aberdeen Group plc now owns 214,056 shares of the company's stock worth $9,001,000 after purchasing an additional 126,153 shares during the period. 67.84% of the stock is currently owned by institutional investors. </p><h2>Insider Buying and Selling</h2><p>In other news, insider Lauren Mastrocola sold 13,600 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $192.08, for a total value of $2,612,288.00. Following the transaction, the insider directly owned 10,442 shares in the company, valued at approximately $2,005,699.36. This trade represents a 56.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Alex Nemiroff sold 25,130 shares of the business's stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total value of $4,852,351.70. Following the completion of the transaction, the general counsel directly owned 20,832 shares of the company's stock, valued at approximately $4,022,450.88. The trade was a 54.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own  2.70% of the company's stock. </p><h2>Praxis Precision Medicines Price Performance</h2><p>Shares of Praxis Precision Medicines stock opened at $261.58 on Thursday. The stock has a market cap of $6.54 billion, a price-to-earnings ratio of -20.28 and a beta of 2.95. The firm's 50-day moving average is $163.26 and its two-hundred day moving average is $87.46. Praxis Precision Medicines, Inc. has a 1 year low of $26.70 and a 1 year high of $278.44. </p><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share for the quarter, topping the consensus estimate of ($3.45) by $0.09.  On average, equities analysts expect that  Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current year. </p><h2>Analyst Ratings Changes</h2><p>PRAX has been the topic of a number of analyst reports. Lifesci Capital raised Praxis Precision Medicines to a &#34;strong-buy&#34; rating in a research note on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft  restated a &#34;buy&#34; rating and set a $303.00 price objective on shares of Praxis Precision Medicines in a report on Friday, December 5th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Praxis Precision Medicines in a research note on Monday. TD Cowen boosted their target price on shares of Praxis Precision Medicines from $251.00 to $353.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Finally, Wedbush  restated an &#34;underperform&#34; rating and issued a $83.00 price target (up from $77.00) on shares of Praxis Precision Medicines in a report on Friday, December 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating and two have assigned  a Sell rating to the company's stock. According to MarketBeat.com, Praxis Precision Medicines  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $333.00.</p><p><b>Get Our Latest Research Report on Praxis Precision Medicines</b></p><h2>Praxis Precision Medicines Company Profile</h2> (Free Report)<p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Praxis Precision Medicines</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>Roth IRA Calculator: Calculate Your Potential Returns</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRAX

<p>HighVista Strategies LLC increased its stake in Praxis Precision Medicines by 71.3% in Q2. Insiders sold shares, reducing their holdings significantly. The stock opened at $261.58, with a market cap of $6.54 billion. Analysts have mixed ratings, with some upgrading to 'strong-buy' and others maintaining 'underperform'. The stock's 1-year high is $278.44.</p>

HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX